Levosimendán Ever Pharma

Levosimendan, the active ingredient in Levosimendán Ever Pharma, is a calcium sensitizer / K‑ATP channel opener presented as an intravenous solution for intravenous use. It is indicated for the treatment of acute decompensated heart failure in adult patients. GNH USA supplies Levosimendán Ever Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of acute cardiac conditions that require inotropic support and vasodilation. - Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. - Cardiogenic shock (when used under specialist supervision): provides inotropic support while reducing afterload. - Heart failure with reduced ejection fraction during acute decompensation: enhances myocardial contractility without increasing intracellular calcium load.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea or vomiting: gastrointestinal discomfort. - Dizziness or light‑headedness: related to blood pressure changes. - Tachycardia: increased heart rate. - Arrhythmias: occasional premature beats.

Serious or Rare Side Effects: - Severe hypotension: may require intervention. - Ventricular arrhythmias: potentially life‑threatening. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: increased ALT/AST. - Electrolyte disturbances: especially potassium shifts.

Levosimendan should be administered with careful clinical monitoring. - Cardiac monitoring: continuous ECG and hemodynamic assessment during infusion. - Blood pressure monitoring: watch for hypotension, especially in patients on other vasodilators. - Renal function: adjust use in severe renal impairment. - Electrolyte balance: correct hypokalemia or hypomagnesemia before initiation. - Contraindication in severe hypotension: avoid if systolic BP < 90 mmHg. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan may interact with several drug classes, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - Concurrent vasodilators (e.g., nitroglycerin, nitroprusside): risk of profound hypotension. - Other inotropes (e.g., dobutamine, milrinone): additive cardiac stimulation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte shifts. - ACE inhibitors or ARBs: combined effect on blood pressure. - Beta‑blockers: may blunt desired inotropic response. - Calcium channel blockers: potential additive vasodilation. - Anti‑arrhythmic agents: monitor for rhythm disturbances.